KindredBio in negotiations for IL-31, eyes four pivotal studies this year

摘要

Kindred Biosciences is in discussions with potential commercial partners for its canine atopic dermatitis treatment.Dechra plans to launch Mirataz in the UK and the EU, while it expects to take on "the necessary regulatory activities to achieve approvals in other key international markets".Mirataz gained fourth-quarter revenues of $1.3m and annual sales of $4.1m in 2019. The product's market penetration is currently at 55% and the reorder rate among purchasing veterinary clinics is up to 71%. KindredBio said the product's average order size continues to increase quarter-over-quarter.On a call with analysts, Dr Chin said: "There was intense interest in the rights to Mirataz from multiple parties."